

ePAT Technologies Limited
ABN 21 146 035 127
Suite 401, 35 Lime Street, Sydney, NSW, 2000
Registered Office: Suite 5, 95 Hay Street Subiaco WA 6008
Phone +61 8 9388 8290
ianhobson@bigpond.com

ASX release: 8th November 2017

ePAT and PainChek™ continue to achieve commercial milestones

- First PainChek™ Residential Aged Care license sale in Australia
- Validation of PainChek™ commercial model
- Developing pipeline of new sales opportunities

ePAT Technologies is pleased to confirm the signing of the first PainChek™ commercial sale with a Residential Aged Care (RAC) operator in South Australia.

Whilst the revenue from this contract is not material, the following factors are material to the Company:

1. Confirmation of the perceived clinical value of PainChek™ within the large RAC market.
2. The sale was also a direct result of Dementia Support Australia (DSA) visiting the RAC facility to provide care to one of the dementia residents, and using PainChek™ to help diagnose pain levels. Subsequently the RAC operator contacted ePAT to purchase a PainChek™ license for pain assessment for all dementia residents on the ward.

“This sale confirms the value proposition of PainChek™ in the RAC market; the value of the DSA relationship as a cost-effective channel to market, and our business model” said Philip Daffas ePAT CEO.

This also comes on the back of a very successful PainChek™ product launch at the Alzheimer’s Australia conference in Melbourne during October 17th-20th 2017; during which Sue Pieters Hawke spoke positively about the value of PainChek™ for people living with dementia in press releases and on national television. “We now have a strong pipeline of leads across large, medium and small RAC providers that we are working on to convert into new commercial sales” added Daffas.


For further information contact:

Ian Hobson
Company Secretary
Tel: +61 8 9388 8290


Philip Daffas
Managing Director
Tel:+61406537235

The PainChek™ Technology:

PainChek™ uses cameras in smartphones and tablets to capture a brief video of the person, which is analysed in real time using facial recognition software to detect the presence of facial micro- expressions that are indicative of the presence of pain.



PainChek™ artificial intelligence assesses facial micro-expressions that are indicative of the presence of pain



PainChek™ six domains of pain assessment that calculates pain severity score

This data is then combined with other indicators of pain, such as vocalisations, behaviours and movements captured to calculate a pain severity score. Due to its speed, ease of use and it's reproducibility, PainChek™ will be able to be used to detect and measure a person's pain, and then further measurements can be used to monitor the effectiveness of pain management.

PainChek™ will be rolled out globally in two phases: first, PainChek™ which is designed for adults who are unable to effectively verbalise their pain such as people with dementia, and second, PainChek™ for Children who have not yet learnt to speak.